ScienceServe agrees to Distribute Redasoft Clone Software in Europe
ScienceServe will distribute in Europe Redasoft’s Visual Cloning genetic map, Redasoft said Feb. 11.
ScienceServe, based in Pegnitz, Germany, will distribute the software in Germany, Switzerland, and Austria.
Redasoft, of Toronto, has designed Visual Cloning with capabilities for restriction analysis primer design, open reading frame search, advanced restriction analysis, a sequence viewer, and a user interface.
Truncated R&D Spending, Small Revenue Rise Helped Genaissance contain Net Loss in Q4
Genaissance Pharmaceuticals Feb. 12 posted $2.6 million in fourth-quarter revenue compared to $2.2 million year over year. R&D spending in the quarter shrank to $4.3 million from nearly $12 million year over year. Fourth-quarter net loss fell to $5.6 million, or $.24 per share, from $11.4 million, or $.50 per share, last year.
The company has approximately $34.2 million in cash, cash equivalents, and securities.
Third Wave Reports Slight Increase in Q4 Revenues as Restructuring Takes its Toll
Third Wave Technologies Feb. 11 reported slightly increased fourth-quarter revenues and narrowed net losses, reversing a trend.
The company brought in $7.6 million in revenues for the period ended Dec. 31 compared to $6.0 million for the same time last year.
At the same time, Third Wave R&D spending fell to $3.3 million in the quarter from $4.8 million year over year. Consequently, net losses in the fourth quarter fell to $486,000 from $16.9 million for the same period in 2001.
The drop in losses comes after a major restructuring that shuttered the company’s in-house oligonucleotide facility for research projects, and reduced the staff from 290 to 165 employees. The company took a $17 million restructuring charge for the year.
Third Wave had $60.3 million in cash, cash equivalents, and short-term investments as of Dec. 31.
Windfall from CombiMatrix Settlement Turbo-charges Nanogen’s Q4 Revenue
Nanogen last week reported a surge in fourth-quarter revenues atop a slight increase in R&D spending and strong net income. However, most of the revenue and earnings were the result of a windfall from a legal settlement last October.
For the period ended Dec. 31, Nanogen reported $12.1 million in revenue, up from $2.3 million one year ago. The company said, however, that receipts from sponsored research fell to $375,000 from $1.2 million year over year. Similarly, sales in the quarter fell to $511,000 from $691,000, Nanogen said.
There were two bright spots in the quarter: contracts and grants increased to $414,000 from $376,000 year over year, and CombiMatrix handed over $10.8 million as part of its defeat in a patent-infringement lawsuit.
Fourth-quarter R&D spending grew to $5.3 million from $4.5 million one year ago. Net income came to $2 million, or $.09 per share, compared with a net loss of $7.5 million, or $.35 per share, in fourth quarter 2001.
Nanogen said it had roughly $53 million in cash, cash equivalents, and short-term investments as of Dec. 31.
NCI Picks Anvil to Screen Certain Lung-Tumor Genes
AnVil will analyze lung tumors for the National Cancer Institute in an attempt to find gene markers for lung cancer diagnostics and treatments, the company said recently.
AnVil, a data management and visualization company based in Burlington, Mass., will use its technologies to explore NCI gene-expression data to help it determine which genes may be linked to lung tumors or normal lung tissue.
Cepheid, Fisher Scientific Expand Smart Cycler Deal
Cepheid said Feb. 10 it has expanded a distribution agreement with Fisher Scientific for its Smart Cycler DNA sequence-detection instrument.
The agreement, which expires in May 2004, gives Fisher non-exclusive rights to distribute the Smart Cycler in US markets that cover life-science and environmental research, pharmaceutical quality control, IVF quality control, and cosmetics quality control. However, the company will not have rights to distribute the instrument in the bio-threat market, according to Cepheid.
Fisher previously was the exclusive distributor of the Smart Cycler systems in the US life science research market. The agreement complements Cepheid’s direct-sales efforts in the US life-science markets, as well as its distribution agreement in several European countries with Izasa; with Bucher in Switzerland, and with Diagnostic Technology in Australia and New Zealand.